Mausolates: Large-Cavity Chelates with Potential as Delivery Vehicles in Nuclear Medicine.

A new type of diborate clathrochelate (cage) ligand featuring nine inwardly pointing nitrogen donors that form a large, rigid cavity, termed a mausolate, is presented. The cavity size and high denticity make this an attractive delivery vehicle for large radionuclides in nuclear medicine. Metal mausolate complexes are stable to air and water (neutral pH) and display extremely high thermal stability (>400 °C). Lanthanide uptake by the mausolate ligand occurs rapidly in solution at room temperature and once complexed, the lanthanide ions are not displaced by a 250-fold excess of a competitive lanthanide salt over more than one week.

Synthesis and Magnetic Studies of Two Neutral, Bis-Ligand Fe(II) Complexes Containing Carbazole-Bis(tetrazole) Ligands.

Previously reported carbazole-bis(tetrazole) (CzTR) ligands (where R = iPr and CH2-2,4,6-C6H2Me3) were used to synthesize air-stable, six-coordinate, octahedral bis-ligand Fe(II) complexes (CzTR)2Fe. The synthesis and characterization of these complexes using 1H nuclear magnetic resonance (NMR), X-ray crystallography, Mössbauer spectroscopy, and density functional theory (DFT) calculations are reported. Analysis of the magnetic properties revealed that the isopropyl derivative displays thermally induced spin crossover (SCO) over a temperature range of 150-350 K. This transition appears as an abrupt two-step transition in the solid state but simplifies to a smooth one-step transition in solution. The two-step transition in the solid state has been postulated to be due to lattice and solvation effects. In contrast, the slightly bulkier substituted CH2-2,4,6-C6H2Me3 (CH2Mes) Fe complex displays dramatically different magnetic behavior with no SCO and magnetic data suggesting low-spin Fe(II) with a possible TIP contribution. DFT calculations support the postulate that the change in magnetic behavior is primarily due to the nature of the ligand substituents.

Theranostic GPA33-Pretargeted Radioimmunotherapy of Human Colorectal Carcinoma with a Bivalent 177Lu-Labeled Radiohapten.

Radiolabeled small-molecule DOTA-haptens can be combined with antitumor/anti-DOTA bispecific antibodies (BsAbs) for pretargeted radioimmunotherapy (PRIT). For optimized delivery of the theranostic γ- and ß-emitting isotope 177Lu with DOTA-based PRIT (DOTA-PRIT), bivalent Gemini (DOTA-Bn-thiourea-PEG4-thiourea-Bn-DOTA, aka (3,6,9,12-tetraoxatetradecane-1,14-diyl)bis(DOTA-benzyl thiourea)) was developed. Methods: Gemini was synthesized by linking 2 S-2-(4-isothiocyanatobenzyl)-DOTA molecules together via a 1,14-diamino-PEG4 linker. [177Lu]Lu-Gemini was prepared with no-carrier-added 177LuCl3 to a molar-specific activity of 123 GBq/µmol and radiochemical purity of more than 99%. The specificity of BsAb-177Lu-Gemini was verified in vitro. Subsequently, we evaluated biodistribution and whole-body clearance for [177Lu]Lu-Gemini and, for comparison, our gold-standard monovalent [177Lu]Lu-S-2-(4-aminobenzyl)-DOTA ([177Lu]Lu-DOTA-Bn) in naïve (tumor-free) athymic nude mice. For our proof-of-concept system, a 3-step pretargeting approach was performed with an established DOTA-PRIT regimen (anti-GPA33/anti-DOTA IgG-scFv BsAb, a clearing agent, and [177Lu]Lu-Gemini) in mouse models. Results: Initial in vivo studies showed that [177Lu]Lu-Gemini behaved similarly to [177Lu]Lu-DOTA-Bn, with almost identical blood and whole-body clearance kinetics, as well as biodistribution and mouse kidney dosimetry. Pretargeting [177Lu]Lu-Gemini to GPA33-expressing SW1222 human colorectal xenografts was highly effective, leading to absorbed doses of [177Lu]Lu-Gemini for blood, tumor, liver, spleen, and kidneys of 3.99, 455, 6.93, 5.36, and 14.0 cGy/MBq, respectively. Tumor-to-normal tissue absorbed-dose ratios (i.e., therapeutic indices [TIs]) for the blood and kidneys were 114 and 33, respectively. In addition, we demonstrate that the use of bivalent [177Lu]Lu-Gemini in DOTA-PRIT leads to improved TIs and augmented [177Lu]Lu-Gemini tumor uptake and retention in comparison to monovalent [177Lu]Lu-DOTA-Bn. Finally, we established efficacy in SW1222 tumor-bearing mice, demonstrating that a single injection of anti-GPA33 DOTA-PRIT with 44 MBq (1.2 mCi) of [177Lu]Lu-Gemini (estimated tumor-absorbed dose, 200 Gy) induced complete responses in 5 of 5 animals and a histologic cure in 2 of 5 (40%) animals. Moreover, a significant increase in survival compared with nontreated controls was noted (maximum tolerated dose not reached). Conclusion: We have developed a bivalent DOTA-radiohapten, [177Lu]Lu-Gemini, that showed improved radiopharmacology for DOTA-PRIT application. The use of bivalent [177Lu]Lu-Gemini in DOTA-PRIT, as opposed to monovalent [177Lu]Lu-DOTA-Bn, allows curative treatments with considerably less administered 177Lu activity while still achieving high TIs for both the blood (>100) and the kidneys (>30).

Current State of 44Ti/44Sc Radionuclide Generator Systems and Separation Chemistry.

In recent years, there has been an increased interest in 44Ti/44Sc generators as an onsite source of 44Sc for medical applications without needing a proximal cyclotron. The relatively short half-life (3.97 hours) and high positron branching ratio (94.3%) of 44Sc make it a viable candidate for positron emission tomography (PET) imaging. This review discusses current 44Ti/44Sc generator designs, focusing on their chemistry, drawbacks, post-elution processing, and relevant preclinical studies of the 44Sc for potential PET radiopharmaceuticals.

Evaluation of hydroxamate-based resins towards a more clinically viable 44Ti/44Sc radionuclide generator.

Several hydroxamate-based resins were synthesized and tested for use in 44Ti/44Sc generator systems in small scale experiments (740 kBq 44Ti). The most promising resin was tested further in larger scale generator studies (37 MBq). This resin displayed impressive retention of 44Ti over several elutions, and high quantities of 44Sc were obtained in small volumes of dilute HCl eluents. Initial radiolabeling experiments were conducted and demonstrated the possibility of direct radiolabeling of the generator produced 44Sc with DOTA.

Engineering CAR-T cells for radiohapten capture in imaging and radioimmunotherapy applications.

Rationale: The in vivo dynamics of CAR-T cells remain incompletely understood. Novel methods are urgently needed to longitudinally monitor transferred cells non-invasively for biodistribution, functionality, proliferation, and persistence in vivo and for improving their cytotoxic potency in case of treatment failure. Methods: Here we engineered CD19 CAR-T cells ("Thor"-cells) to express a membrane-bound scFv, huC825, that binds DOTA-haptens with picomolar affinity suitable for labeling with imaging or therapeutic radionuclides. We assess its versatile utility for serial tracking studies with PET and delivery of α-radionuclides to enhance anti-tumor killing efficacy in sub-optimal adoptive cell transfer in vivo using Thor-cells in lymphoma models. Results: We show that this reporter gene/probe platform enables repeated, sensitive, and specific assessment of the infused Thor-cells in the whole-body using PET/CT imaging with exceptionally high contrast. The uptake on PET correlates with the Thor-cells on a cellular and functional level. Furthermore, we report the ability of Thor-cells to accumulate cytotoxic alpha-emitting radionuclides preferentially at tumor sites, thus increasing therapeutic potency. Conclusion: Thor-cells are a new theranostic agent that may provide crucial information for better and safer clinical protocols of adoptive T cell therapies, as well as accelerated development strategies.

Synthesis and crystal structures of tetra-meric [2-(4,4-dimethyl-2-oxazolin-2-yl)anilido]sodium and tris-[2-(4,4-dimethyl-2-oxazolin-2-yl)anilido]ytterbium(III).

Reaction of 2-(4,4-dimethyl-2-oxazolin-2-yl)aniline (H2-L1) with one equivalent of Na[N(SiMe3)2] in toluene afforded pale-yellow crystals of tetra-meric poly[bis-[µ3-2-(4,4-dimethyl-2-oxazolin-2-yl)anilinido][µ2-2-(4,4-dimethyl-2-oxa-zolin-2-yl)aniline]tetra-sodium(I)], [Na4(C11H13N2O)4] n or [Na4(H-L1)4] n (2), in excellent yield. Subsequent reaction of [Na4(H-L1)4] n (2) with 1.33 equivalents of anhydrous YbCl3 in a 50:50 mixture of toluene-THF afforded yellow crystals of tris-[2-(4,4-dimethyl-2-oxazolin-2-yl)anilinido]ytterbium(III), [Yb(C11H13N2O)3] or Yb(H-L1)3 (3) in moderate yield. Direct reaction of three equivalents of 2-(4',4'-dimethyl-2'-oxazolin-yl)aniline (H2-L1) with Yb[N(SiMe3)2]3 in toluene resulted in elimination of hexa-methyl-disilazane, HN(SiMe3)2, and produced Yb(H-L1)3 (3) in excellent yield. The structure of 2 consists of tetra-meric Na4(H-L1)4 subunits in which each Na+ cation is bound to two H-L1 bridging bidentate ligands and these subunits are connected into a polymeric chain by two of the four oxazoline O atoms bridging to Na+ cations in the adjacent tetra-mer. This results in two 4-coordinate and two 5-coordinate Na+ cations within each tetra-meric unit. The structure of 3 consists of a distorted octa-hedron where the bite angle of ligand L1 ranges between 74.72 (11) and 77.79 (11) degrees. The oxazoline (and anilide) N atoms occupy meridional sites such that for one ligand an anilide nitro-gen is trans to an oxazoline nitro-gen while for the other two oxazoline N atoms are trans to each other. This results in a significantly longer Yb-N(oxazoline) distance [2.468 (3) Å] for the bond trans to the anilide compared to those for the oxazoline N atoms trans to one another [2.376 (3), 2.390 (3) Å].

(µ-Di-tert-butyl-silanediolato)bis-[bis-(η5-cyclo-penta-dien-yl)methyl-zirconium].

The reaction of t-Bu2Si(OH)2 with two equivalents of Cp2Zr(CH3)2 produces the title t-Bu2SiO2-siloxide bridged dimer, [Zr2(CH3)2(C5H5)4(C8H18O2Si)] or [Cp2Zr(CH3)]2[µ-t-Bu2SiO2] (1), where one methyl group is retained per zirconium atom. The same product is obtained at room temperature even when equimolar ratios of the silanediol and Cp2Zr(CH3)2 are used. Attempts to thermally eliminate methane and produce a bridging methyl-ene complex resulted in decomposition. The crystal structure of 1 displays typical Zr-CH3 and Zr-O distances but the Si-O distance [1.628 (2) Å] and O-Si-O angle [110.86 (15)°] are among the largest observed in this family of compounds suggesting steric crowding between the t-Bu substituents of the silicon atom and the cyclo-penta-dienyl groups. The silicon atom lies on a crystallographic twofold axis and both Cp rings are disordered over two orientations of equal occupancy.

Variable coordination of carbazolyl-bis(tetrazole) ligands in lanthanide chemistry.

The synthesis of the protioligand 1,8-bis(2'-isopropyltetrazo-5'-yl)-3,6-di-tert-butylcarbazole, HCzTiPr2, is described. The acid-base reaction of 2 with various Ln[N(SiMe3)2]3 (Ln = Ce, Sm, Er, Yb, Y) precursors leads to products displaying a variety of different bonding modes for the CzTiPr- ligand as revealed by X-ray crystallographic studies. The smaller lanthanides form Ln(CzTiPr)[N(SiMe3)2]2 complexes (Ln = Er (3), Yb(4)) with a near planar, tridentate coordination mode for the CzTiPr- ligand. In contrast, the larger lanthanides form Ln(CzTiPr)2[N(SiMe3)2] complexes (Ln = Ce (5), Sm (6)) at room temperature that feature a sandwich structure with a highly distorted tridentate mode where tetrazole canting allows the metal to sit well out of the carbazole plane. Attempts to force additional CzTiPr- ligands onto Er or Yb at elevated temperature results in isolation of trace siloxide complexes Ln(CzTiPr)2(OSiMe3) (Ln = Er (3a), Yb (4a)) that adopt a flat tridentate ligand bonding mode similar to 3 and 4. Surprisingly, the high temperature reaction of 2 with Y[N(SiMe3)2]3 affords Y(CzTiPr)3, 7, featuring two tridentate and one bidentate CzTiPr ligands. Partial hydrolysis of 6 occurs over time to produce a hydroxo-bridged dimer that also features one bridging and one bidentate CzTiPr ligand, Sm(κ3-CzTiPr)(κ3-µ-CzTiPr)(µ-OH)2Sm(κ3-CzTiPr)(κ2-CzTiPr), 6a, further illustrating the remarkable coordinative flexibility of the CzTiPr ligand system.